Co-administration of Lacidipine (Lacipil) with other agents recognised to have a hypotensive effect, including anti-hypertensive agents, (e.g. diuretics, beta-blockers, or ACE inhibitors), may have an additive hypotensive effect. However, no specific interaction problems have been identified in studies with common antihypertensive agents (e.g. beta-blockers and diuretics) or with digoxin, tolbutamide or warfarin.
The plasma level of Lacidipine (Lacipil) may be increased by simultaneous administration of cimetidine.
Lacidipine (Lacipil) is highly protein bound (more than 95%) to albumin and alpha-1-glycoprotein.
As with other dihydropyridines, Lacidipine (Lacipil) should not be taken with grapefruit juice as bioavailability may be altered.
In clinical studies in patients with a renal transplant treated with cyclosporin, Lacidipine (Lacipil) reversed the decrease in renal plasma flow and glomerular filtration rate induced by cyclosporin.
Lacidipine is known to be metabolised by cytochrome CYP3A4 and, therefore, significant inhibitors and inducers of CYP3A4 administered concurrently may interact with the metabolism and elimination of lacidipine.
Other Services
Country
Account